Clinical Insights for Breast Surgeons and Radiologists Evaluating Post-Cryoablation Breast Imaging
As breast cancer cryoablation continues to gain attention as a minimally invasive, image-guided local treatment option for carefully selected patients with low-risk breast cancer, one of the most important clinical questions is how to interpret follow-up imaging after treatment.
In this short video segment from IceCure’s 2026 American Society of Breast Surgeons (ASBrS) symposium, Robert C. Ward, MD, Associate Professor of Radiology at The Warren Alpert Medical School of Brown University, shares practical guidance on expected and suspicious imaging findings following breast cancer cryoablation
Complete the form to watch the full-length video and learn how post-cryoablation breast imaging may be evaluated across modalities.
What you’ll learn in this video:
- Recognize expected multi-modality imaging findings after breast cancer cryoablation
- Understand the strengths and limitations of mammography, ultrasound, MRI, and contrast-enhanced imaging in follow-up assessment
- Differentiate expected post-treatment changes from findings that may require further evaluation
- Explore practical considerations for collaboration between breast surgeons and radiologists in post-cryoablation surveillance
Why post breast cancer cryoablation matters?
Post-cryoablation imaging is an important component of clinical follow-up as more practices evaluate cryoablation for selected patients with biologically low-risk, early-stage breast cancer. This educational segment is designed to support clinician understanding of imaging appearance over time and reinforce the multidisciplinary workflow needed for appropriate patient monitoring.
About the speaker: Robert C. Ward, MD
Robert C. Ward, MD is Associate Professor of Radiology at The Warren Alpert Medical School of Brown University and Associate Chief, Department of Radiology, Women & Infants Hospital. In this symposium segment, Dr. Ward reviews what clinicians may expect to see on follow-up breast imaging after cryoablation and how to approach findings that warrant closer evaluation.
About ProSense® Cryoablation For Breast Cancer
IceCure’s ProSense® System uses liquid nitrogen-based cryoablation technology to destroy targeted tissue through a minimally invasive, image-guided approach performed under local anesthesia. ProSense® has received FDA marketing authorization for the local treatment of breast cancer in women aged 70 and older with biologically low-risk tumors measuring ≤1.5 cm who receive adjuvant endocrine therapy.
Watch the segment or the full length video
Complete the form on this page to access Dr. Ward’s full ASBrS symposium segment on breast cancer cryoablation follow-up imaging and gain clinically relevant insight for breast surgery and breast imaging practice. If you would like to view the entire symposium “Unlocking De-Escalation of Care: Breast Cancer Cryoablation” you can click here.
This symposium was supported by IceCure Medical through a marketing grant. It was not part of the official ASBrS Annual Meeting program, and no AMA PRA Category 1 Credits™ are assigned to it by the ASBrS.